Page 6,733«..1020..6,7326,7336,7346,735..6,7406,750..»

Research and Markets: Autism Spectrum Disorders – Public Awareness and Physician Detailing will Drive Market Growth

Posted: Published on June 26th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/cn48wt/case_study_autism) has announced the addition of the "Case Study: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth" report to their offering. This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway. To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals) are both approved in the US for the treatment of irritability associated with autistic disorder. Scope - Examination of key recommendations contained in published treatment guidelines for the management of ASDs. - Overview of the treatment pathway and identification of three key points of influence that may be targeted by pharmaceutical companies. - Discussion of key opportunities and threats facing existing and prospective players in the autism spectrum disorders market. Key Topics Covered: OVERVIEW Originally posted here: Research and Markets: Autism Spectrum Disorders - Public Awareness and Physician Detailing will Drive Market Growth … Continue reading →

Comments Off on Research and Markets: Autism Spectrum Disorders – Public Awareness and Physician Detailing will Drive Market Growth

Research and Markets: R&D Trends: Autism Spectrum Disorders – Pipeline Growth Reflects Increasing Interest in Autism

Posted: Published on June 26th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vlhmzc/randd_trends_auti) has announced the addition of the "R&D Trends: Autism Spectrum Disorders - Pipeline Growth Reflects Increasing Interest in Autism" report to their offering. This report reviews the key trends in the autism spectrum disorders pipeline. The analysis is intended to support R&D decision-making by evaluating the dynamics of the pipeline and hypothesizing future treatments of autism spectrum disorders. The autism spectrum disorders (ASDs) market is a challenging one to penetrate; since 2006 only two products have been successful in entering this marketplace: Risperdal (risperidone; Johnson & amp; Johnson) and Abilify (aripiprazole; Bristol-Myers Squibb). However, as additional agents near the market, increasing interest in ASDs has led to a sizable growth in the clinical pipeline. Scope - Overview of drugs in late- and early-stage clinical development for autism spectrum disorders. - Identification of the target product profile for future autism spectrum disorders treatments. - Summary of clinical trial design in autism spectrum disorders including exploration of key endpoints and assessment methodology. - Identification of key challenges associated with the conduct of clinical trials in autism spectrum disorders. - Exploration of future treatment in autism spectrum disorders including the development of personalized treatments and the use … Continue reading →

Comments Off on Research and Markets: R&D Trends: Autism Spectrum Disorders – Pipeline Growth Reflects Increasing Interest in Autism

Hormonal treatment associated with better test performance after stroke

Posted: Published on June 26th, 2012

Public release date: 25-Jun-2012 [ | E-mail | Share ] Contact: Aaron Lohr alohr@endo-society.org 240-482-1380 The Endocrine Society Stroke patients treated who received hormonal treatment, combined with rehabilitation, performed better on functioning and reasoning tests than patients who received rehabilitative therapy alone, a new clinical study from Italy shows. The results will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston. In the United States, stroke is the fourth-leading cause of death. The disease occurs when a blood vessel to the brain either ruptures (hemorrhagic stroke), or is obstructed by a clot during an ischemic stroke, which is the most common type. Inadequate blood flow prevents oxygen from reaching parts of the brain, which can lead to tissue death and serious long-term disability. The hormone, relaxin, or RLX, is a naturally occurring protein produced by the reproductive organs in men and women, although only women have circulating hormone in the blood, both during ovulation and pregnancy. For years after its discovery in 1926 by the renowned zoologist and reproductive endocrinologist Frederick Hisaw, the hormone's primary role was thought to be that of relaxing the uterus and pelvis for childbirth. More recently, however, research from this study's investigators, … Continue reading →

Comments Off on Hormonal treatment associated with better test performance after stroke

UPDATE – InVivo Therapeutics’ CEO Frank Reynolds Scheduled Appearance on WAWS-TV (FOX)/WTEV-TV (CBS) in Jacksonville …

Posted: Published on June 26th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds scheduled appearance on WAWS-TV (FOX)/WTEV-TV (CBS) in Jacksonville, Florida on Monday June 25, 2012 at 7:45 am EDT has been postponed due to tropical storms. The segment will be taped and aired on tomorrows program. He is also scheduled to appear on KNSD-TV (NBC) in San Diego, California on Tuesday June 26, 2012 at 12:00pm PDT. InVivo Therapeutics has pioneered a new treatment using a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord. The device sparesspinal cordtissue from scarring while improving functional recovery after a traumatic SCI. In addition to the scaffold and its application for acute and chronic SCI, Reynolds will discuss new hydrogel technologies under development by InVivo. Our technology is a true platform that can be leveraged to create many neurotrauma products. InVivo is developing technologies to treat both acute and chronic injuries, as well as therapies for other nervous system conditions such as pain due to nerve compression and other peripheral nerve injuries. Were currently under review at FDA for our first SCI treatment, and … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on UPDATE – InVivo Therapeutics’ CEO Frank Reynolds Scheduled Appearance on WAWS-TV (FOX)/WTEV-TV (CBS) in Jacksonville …

Berg Pharma and the Parkinson's Institute ink R&D collaboration to drive disease understanding and accelerate …

Posted: Published on June 26th, 2012

CAMBRIDGE, Mass. and SUNNYVALE, Calif., June 25, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company and the renowned Parkinson's Institute announced a unique partnership that would enable a more robust modeling in the investigation of Parkinson's Disease (PD). There are approximately one million Americans who live with the disease with 50,000 new cases per year and this rate is expected to rise with an aging baby boomer population. The underlying pathophysiology and disease understanding of PD still remains elusive due to a combination of disease complexity and lack of predictive capability of existing models. (Logo: http://photos.prnewswire.com/prnh/20120404/CL82745LOGO) Dr. William Langston, Founder, Scientific Director, and CEO of the Parkinson's Institute said, "We believe that with the in depth knowledge of Parkinson's disease we have at the Institute and the exciting new Berg Interrogative Biology platform, there is a real possibility that we accelerate our mission of finding the cause and cure for the disease, for these reasons we are very excited about this collaboration." The hallmark discovery of the association of MPTP and parkinsonism in 1982 by Dr. William Langston, an internationally renowned neurology researcher and advisor to the Michael J. Fox Foundation, opened the field up to research and today … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Berg Pharma and the Parkinson's Institute ink R&D collaboration to drive disease understanding and accelerate …

Parkinson's is much more than dopamine

Posted: Published on June 26th, 2012

and much more than motor symptoms. A colleague handed me this paper, not just as an interesting aspect of Parkinsons, but as somewhat supportive paper for the role of serotonin in depression. I have said before that I think the serotonin theory of depression (as depicted in Zoloft commercials) is probably wrong, but my views are actually a bit more nuanced than that. The serotonin theory is probably wrong, but not because it is wrong, rather, it is oversimplified. I think that low serotonin levels on their own probably dont cause depression, but it looks like there may still be a role for serotonin in depressive symptoms, and this paper seems to agree. Science, its always more complicated than you think at first. Politis et al. Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinsons Patients Treated with Dopamine Grafts Sci Trans Med, 2012. Parkinsons is something that no one wants to get. Its a degenerative disorder of the nervous system, which results in a wide variety of symptoms. Most people think of Parkinsons and picture a shuffling gait, severe hand tremor, slowness of movement and rigidity. But there are other symptoms as well, include depression, hallucinations, fatigue, sleep disturbances, … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Parkinson's is much more than dopamine

Family launches fight for West Kingsdown boy's vital operation

Posted: Published on June 26th, 2012

CHRISTIAN Wells is a "happy little boy", even though his cerebral palsy means he can only watch while his two sisters run and play together. The West Kingsdown toddler, now almost two the oldest of three siblings delivered 12 weeks prematurely depends on a frame to walk. Hope: Christian Wells with mum and dad Laura and Steve, and sisters Katie and Dani Christian Wells who has cerebral palsy TWLD20120608H-002_C Christian Wells who has cerebral palsy, with his mum and dad Laura and Steve and his sisters Katie and Dani TWLD20120608H-004_C His mum had laser surgery inside the womb to save all three children and there was a 50 per cent chance of their surviving. All were born safely and are now nearly two but Christian was diagnosed with cerebral palsy at 13 months, after his parents Steve and Laura noticed he was not developing at the same rate as his siblings. Doctors believe his condition is due to his premature birth, which broke some of the nerves that connect his legs to his brain. Now Mr and Mrs Wells, of Fawkham Road, are hoping to fly Christian to America for an operation which would enable him to walk unaided and … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Family launches fight for West Kingsdown boy's vital operation

Saints center de la Puente to host benefit for brain-injury care

Posted: Published on June 26th, 2012

As a professional football player who takes jarring hits, San Clemente's Brian de la Puente is keenly aware that a traumatic brain injury could change his life. Such injuries already have done that to two of his friends. New Orleans Saints center Brian de la Puente, a 2003 graduate of San Clemente High School, will be at Hapa J's restaurant in his hometown to host a July 3 fundraiser for the Brain Trauma Foundation. PAUL RODRIGUEZ, THE ORANGE COUNTY REGISTER ADVERTISEMENT So, de la Puente, the New Orleans Saints center who snapped the ball that quarterback Drew Brees threw to break the National Football League's single-season record for passing yards last year, is asking the public to help him raise money for the Brain Trauma Foundation. The organization aims to educate athletes, coaches, nurses, parents and health-care professionals on recognizing the symptoms of concussions so victims can get early and appropriate care. It also does research intended to broaden the treatments available. De la Puente and his wife, Makenzie, will host a July 3 fundraiser called "Defend Your Dome" using an image of New Orleans' Superdome as the logo from 4:30 p.m. to closing at Hapa J's restaurant, 2016 S. … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Saints center de la Puente to host benefit for brain-injury care

Coping with MS: Ann Romney's health struggle

Posted: Published on June 26th, 2012

Ann Romney was diagnosed with multiple sclerosis in 1998. When I interviewed her for Fox News at our Washington Bureau two weeks ago, she readily admitted to me how difficult the diagnosis was at first, leading to fear, uncertainty and dark times. She characterized her recurrent symptoms as including profound fatigue (which she could readily distinguish as her MS fatigue), weakness, and problems thinking clearly. She acknowledged that stress plays a major role in her ability to cope with and respond to this difficult disease. Like more than 400,000 other MS sufferers in the U.S. and 2.5 million around the world, Romney lives in anticipation of her next exacerbation, which can come at any time. In addition to fatigue, weakness, and affects on thinking, other characteristic symptoms for MS sufferers include visual loss, sensory loss, problems with balance, pain, and in up to one third of cases, wheelchair-necessitating paralysis. MS is known medically as one of our great imitators, because it can mimic the symptoms of many other neurological diseases. If you consider nerves to be like electrical wires, then MS is due to damage to the covering of the wires (myelin sheath), leading to abnormal conduction. It is now … Continue reading →

Posted in MS Treatment | Comments Off on Coping with MS: Ann Romney's health struggle

Federal court backs Teva Pharmaceutical patents behind MS treatment Copaxone

Posted: Published on June 26th, 2012

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a U.S. federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple sclerosis treatment Copaxone. The Israeli company said Saturday the decision from the U.S. District Court for the Southern District of New York covers several patents, the last of which expires in 2015, and that it prevents other drugmakers from selling their versions of the drug until then. It also said the decision should prevent the Food and Drug Administration from approving generic versions of the drug until 2014. U.S.-traded shares of the company rose 4.5 per cent, or $1.71, to close at $39.72, while the Standard & Poor's 500 index fell 1.6 per cent. Teva had sued Mylan Laboratories Inc., Momenta Pharmaceuticals Inc., Sandoz Inc. and Natco Pharmaceuticals, accusing the rival companies of infringing on patents covering the drug's chemical composition, method of use and the manufacturing process behind the product. Teva is the 10th largest global pharmaceutical company, according to drug data firm IMS Health, and Copaxone is its main brand-name offering. It expects $3.8 billion in sales this year from the drug. Teva is primarily a maker of generic drugs. … Continue reading →

Posted in MS Treatment | Comments Off on Federal court backs Teva Pharmaceutical patents behind MS treatment Copaxone

Page 6,733«..1020..6,7326,7336,7346,735..6,7406,750..»